Health & Wellness

Core One Labs Rejuvenates Their Presence

  • Edge Editorial Team

    At Edge Investments, we make investing in small cap stocks enjoyable and edge-ucational. We are here to teach you about investing, keep you up to date on news, and help connect you with companies that you may have a desire to invest in.

    View all posts

There seems to be plenty on the horizon for Core One Labs (CANADA: COOL) (U.S.: CLABF) (EUROPE: LD62). 

See what we did there? 

If not, you’ll understand when you see the next paragraph. 

Anyways, the strategies Core One has been executing this year as Q1 wraps up seem to be far more effective than our puns. 

Over the last year, the company has established a strong presence the world of biotechnology research and technology life sciencesWith unique applications of synthetic psilocybin, strategic acquisitions of clinics such as Ketamine Infusion Centers of Texas Inc., and listing applications to the NASDAQ, it’s clear that a diversified approach within psychedelics is coming quickly. 

With Core One Labs moving this fast, its crucial we keep you updated with snapshots of the company as they work towards becoming a key player in this sector. 

The Psychedelic Stock Index 

The Horizons Psychedelic ETF, launched by Horizons ETFs Management in Canada, began trading in January 2021 under the ticker $PSYK on the NEO Exchange. Core One is one of 23 public companies in this index, after recently being fast-tracked onto the world’s first psychedelic ETF on March 19 of this year. 

The companies involved are listed on various exchanges around the U.S. and Canada, and all have significant business and exposure in the industry of psychedelics. $PSYK will track the current underlying North American Psychedelics Index, while Solactive AG, hailing from Germany, will be taking care of tracking the ETF’s net asset value as it assumes the role of independent calculation agent for the index. 

“Recent breakthroughs in research and increased support from the scientific and medical communities have led to a rapidly growing psychedelics as alternative treatment industry. The Horizons Psychedelic ETF provides investors diversified exposure to the overall growth of the sector, which has gained tremendous interest from global investors and investment funds. We are honored to be included in the PSYK ETF, and in the Company of some very well-respected peers,” stated Joel Shacker, CEO of Core One Labs. “The Company’s fast entry inclusion into the fund is a great milestone for us and signifies growing awareness and increasing confidence within the investment community about Core One Labs. We look forward to growing our investor base and to the additional exposure we will witness as a result of this significant event.”

Rejuva Brings On 20 Years of Physician Experience 

Already boasting an impressive collection of clinics and a client database of over 275,000 patients among them, Core One is well on its way to obtaining regulatory research approval for “the advancement of psychedelic-derived treatments for mental health disorders.”

COOL’s wholly owned clinic subsidiary, Rejuva Mental Health Clinic, has brought on Dr. Stephen Peach as the lead physician. One of the focal reasons to have a strategic role like Dr. Peach’s is the comprehensive patient intake and assessment protocols. Determining a client’s mental health needs based on their history of disorder and/or addiction and administering the use of new alternative medicines such as psychedelics, is no simple feat. This is where 20 years of experience in the medical field proves crucial, as Core One needs to pave the way for these kinds of protocols in this relatively new of mental health treatment. 

“We are very excited to have Dr. Stephen Peach lead the Rejuva clinic,” stated the Company’s CEO, Joel Shacker. “Dr. Peach has extensive experience in the medical field and through his practice in family and emergency medicine, he has witnessed firsthand the need for alternative medicines to address issues such as depression, anxiety and addiction. A growing number of clinical studies provide empirical support that the use of psychedelics as an alternative medicine are providing mental health patients and those afflicted by addiction with sustained benefits, when combined with therapy.” Markets & Marketing 

Knowing they are on the brink of a new wave of healthcare and alternative treatment, Core One has successfully entered marketing and consulting agreements with two different kinds of companies. While Core One is certainly still in an emerging sector, the potential of companies in the psilocybin sector to achieve relevance within the global biopharma industry seems to become clearer as the days go by.  

Such is the reason the company entered two 2-month marketing agreements, one with a company that specializes in emerging markets, and another that has been around for nearly a decade that can appeal to the more established side of the market, such as the biotech-heavy NASDAQ; in which the company has recently applied to list on. 

As a first step to getting into the United States, the Financial Industry Regulatory Authority (FINRA) has accepted Core One’s application to list on the OTC pink market, down in the United States. This creates an established, transparent presence for the company in the U.S. and improves market liquidity, with visibility such as “level ll” quotes being available on the OTC market databases. For those who don’t know, “level ll” is a more in depth look at the upcoming bid and ask spread for any given stock, showing not only who is trying to buy or sell a stock at what price, but lot sizes as well.  

“We are very excited to be trading on the OTC Pink Market. This milestone opens Core One Labs to a broader market and larger investor base, while also providing current and prospective shareholders greater accessibility and liquidity in the trading of the Company’s common shares. Additionally, this US listing, in general, will provide greater exposure for the Company in the rapidly growing emerging psychedelics as alternative medicine space.” stated Joel Shacker CEO of the Company. 

Disclaimer: Core One Labs Inc. is an Edge Communications Client, and we own shares in the company.  


  • Edge Editorial Team

    At Edge Investments, we make investing in small cap stocks enjoyable and edge-ucational. We are here to teach you about investing, keep you up to date on news, and help connect you with companies that you may have a desire to invest in.

    View all posts

Leave a Comment

Get 30+ hours of analyst research directly in your inbox weekly. Sign-up today to stay on top of the market.